RxDoctor Payments DataLook up a doctor →

Joseph Reardon, MD

Family Medicine · Searcy, ARNPI 1801858188

Payments from drug & device makers

$14,668in general payments, 2019–2025

Across 941 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • AbbVie$1K
  • GSK$1K
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$14,46299%
  • Education$2051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,668 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$168,340
Medicare patients
395
Services billed
8,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$149,626
EliquisApixaban126$127,181
JardianceEmpagliflozin114$93,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$54,798
TrulicityDulaglutide45$51,092
Tresiba Flextouch U-200Insulin Degludec53$47,771
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$44,865
MounjaroTirzepatide27$35,935
RexultiBrexpiprazole24$33,570
MyrbetriqMirabegron26$23,631
EntrestoSacubitril/Valsartan23$18,524
XareltoRivaroxaban16$12,013
SymbicortBudesonide/Formoterol Fumarate31$10,579
RybelsusSemaglutide11$9,150
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,777$158,776152 claims
PfizerEliquis$725$127,181126 claims
Boehringer IngelheimJardiance$965$93,466114 claims
Lilly USA, LLCTrulicity, Mounjaro$1,492$87,02772 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,119$63,33391 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,873$60,144101 claims
Otsuka America Pharmaceutical, Inc.Rexulti$204$33,57024 claims
Astellas Pharma US IncMyrbetriq$622$23,63126 claims
NovartisEntresto$81$18,52423 claims
Johnson & JohnsonXarelto$121$12,01316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →